Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer
出版年份 2022 全文链接
标题
Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer
作者
关键词
-
出版物
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 238, Issue -, Pages 114424
出版商
Elsevier BV
发表日期
2022-05-10
DOI
10.1016/j.ejmech.2022.114424
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Discovery of 2,4‐diaminopyrimidine derivatives targeting p21‐activated kinase 4: Biological evaluation and docking studies
- (2020) Qiaohua Qin et al. ARCHIV DER PHARMAZIE
- Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer
- (2020) Zhong Y. Yeow et al. NATURE
- TRIM37 controls cancer-specific vulnerability to PLK4 inhibition
- (2020) Franz Meitinger et al. NATURE
- Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant
- (2020) Xiaoyang Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Emerging insights into symmetry breaking in centriole duplication: updated view on centriole duplication theory
- (2020) Shohei Yamamoto et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer
- (2019) Amreena Suri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cep131 overexpression promotes centrosome amplification and colon cancer progression by regulating Plk4 stability
- (2019) Dong Hyun Kim et al. Cell Death & Disease
- PLK4: a promising target for cancer therapy
- (2019) Yi Zhao et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Cytochrome P450 research and The Journal of Biological Chemistry
- (2018) F. Peter Guengerich JOURNAL OF BIOLOGICAL CHEMISTRY
- Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma
- (2018) Ryan A. Denu et al. MOLECULAR CANCER RESEARCH
- Downregulation of miR-10B* is correlated with altered expression of mitotic kinases in osteosarcoma
- (2018) Gabriela Molinari Roberto et al. PATHOLOGY RESEARCH AND PRACTICE
- Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers
- (2018) Masanori Kawakami et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Polo-like kinases and acute leukemia
- (2018) Oksana Goroshchuk et al. ONCOGENE
- YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect
- (2018) Qian Lei et al. Cell Death & Disease
- Novel pyrazolo[3,4- d ]pyrimidine with 4-(1 H -benzimidazol-2-yl)-phenylamine as broad spectrum anticancer agents: Synthesis, cell based assay, topoisomerase inhibition, DNA intercalation and bovine serum albumin studies
- (2017) Prinka Singla et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- PLK4: a link between centriole biogenesis and cancer
- (2017) Radhika Radha Maniswami et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- TRIM37, a novel E3 ligase for PEX5-mediated peroxisomal matrix protein import
- (2017) Wei Wang et al. JOURNAL OF CELL BIOLOGY
- Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives as Potent and Selective p21-Activated Kinase 4 (PAK4) Inhibitors
- (2017) Chenzhou Hao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and biological evaluation of (E)-4-(3-arylvinyl-1H-indazol-6-yl)pyrimidin-2-amine derivatives as PLK4 inhibitors for the treatment of breast cancer
- (2017) Zhihao Liu et al. RSC Advances
- Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts
- (2016) Ines Lohse et al. Oncotarget
- Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy
- (2016) Zhenhua Li et al. Journal of Cancer
- Understanding the Polo Kinase machine
- (2015) V Archambault et al. ONCOGENE
- Reversible centriole depletion with an inhibitor of Polo-like kinase 4
- (2015) Y. L. Wong et al. SCIENCE
- The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent
- (2014) Peter B. Sampson et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3′[3H]indol]-2′(1′H)-ones as Orally Bioavailable Antitumor Agents
- (2014) Peter B. Sampson et al. JOURNAL OF MEDICINAL CHEMISTRY
- PLK4 overexpression and its effect on centrosome regulation and chromosome stability in human gastric cancer
- (2014) Kazuya Shinmura et al. MOLECULAR BIOLOGY REPORTS
- Discovery of a Highly Potent, Orally Active Mitosis/Angiogenesis Inhibitor R1530 for the Treatment of Solid Tumors
- (2013) Jin-Jun Liu et al. ACS Medicinal Chemistry Letters
- Preclinical evaluation of the novel multi-targeted agent R1530
- (2011) Kenneth Kolinsky et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Role of Human Liver Microsomes in In Vitro Metabolism of Drugs—A Review
- (2009) Sepuri Asha et al. APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started